The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
None
None
0 to 18 years of age presenting for treatment in any of the unit selected to carry out the recommandations
Cohort
Prospective
Not listed
Feasibility of these recommendations
Availability of drugs. This is part of the project as we are working with Low or low to Middle Income countries.
Correct application of therapeutic recommendations
Availability of drugs and adherence to protocol: Some centers may at times have to find locally the chemiotherapy for application of the protocol. The capacity of the units to do this is alos being studied. By looking at why treatment was not given. Was it because of lack of discipline regarding the attendance at the units for treatment, transport, accommodation, or medication not available ?
Complete Remission Rate (CR) close to 85% after induction
Evaluation of the CR j34 or J42 depending on the risk level High or standard.
Ability to follow treatment:
The number of children who stop treatment without the consent of the doctor.
Survival without relapse of patients
the number of children in complete remission without relapse at the end of treatment .
Click on the lead sponsor to view all of their trials.
French Africa Pediatric Oncology Group
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator